Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole once-weekly formulations PK study in schizophrenia
jRCT2080223873Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brexpiprazole in schizophrenia, sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Pharmacokinetics of brexpiprazole QW formulations vs conventional tablet and Safety and tolerability of brexpiprazole QW formulations. Started Apr 2018; status: completed.
02
Drugs
brexpiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2080223873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223873.